Revenue segments as reported by the company.

Premiums

Product revenue

Administrative fees and other revenue

Net investment income

Net gains on financial instruments

Gain on sale of business

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit expense

Selling, general and administrative

Interest expense

Amortization of other intangible assets

Loss on extinguishment of debt

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Elevance Health Inc

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. The firm supports consumers, families, and communities across the entire care journey, connecting them to the care, support, and resources they need to lead healthier lives. It offers health plans and clinical, behavioral, pharmacy, and complex-care solutions which promote whole health. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elevance Health reports robust Q4 earnings, eyes margin optimization

Elevance Health's strong Q4 2022 performance, strategic acquisitions, and focus on margin optimization position the company for continued growth. With a clear outlook for 2023, emphasizing membership expansion and margin recovery, the company is poised for success. Challenges in optimizing margins and managing cost structures are balanced by growth opportunities and strategic initiatives.

Elevance Health reports robust Q1 growth and innovation in healthcare

Elevance Health Inc demonstrated strong financial performance and growth in Q1 2023, driven by increased membership and solid operating results.
The company's focus on advocacy, innovation, and sustainability, along with strategic investments in healthcare capabilities, positions it for continued success.
While facing challenges in cost management and strategic partnerships, Elevance Health is well-positioned to capitalize on opportunities in specialty care and value-based models.
Overall, Elevance Health's commitment to whole health, innovation, and value-based care sets a positive trajectory for future growth and industry leadership.

Elevance Health Inc posts robust Q2 earnings, eyes value-based care

Elevance Health Inc reported strong Q2 earnings, raised adjusted EPS outlook to over $32.85 for the year, and emphasized a focus on value-based care and digital solutions. While facing margin pressure in Carelon, the company remains confident in its strategy execution and performance for 2023 and beyond.

Elevance Health excels in Q3, eyes growth through strategic actions

Elevance Health's Q3 performance was strong, with a focus on operational efficiency and strategic investments. Challenges in Medicare ratings were addressed through proactive measures, while opportunities lie in growth acceleration and strategic partnerships. The company remains on track to achieve its long-term growth targets.

Elevance Health Inc surpasses earnings expectations, eyes growth opportunities

Elevance Health Inc's strong financial performance in Q4 2023 and full-year results, coupled with strategic initiatives in expanding capabilities and enhancing operational efficiency, position the company for continued success. Challenges in commercial repricing and Medicaid dynamics are being addressed, while opportunities in Medicare Advantage and strategic investments offer avenues for growth.

Elevance Health posts robust Q1 earnings, eyes strategic growth

Elevance Health demonstrated strong financial performance in Q1, with revenue growth and margin expansion in key segments.
While facing challenges like potential Medicare rate cuts, the company is leveraging partnerships and acquisitions for growth.
Opportunities lie in expanding service offerings, geographic footprint, and optimizing Medicaid margins for long-term sustainability.

Elevance Health Inc reports robust earnings growth and strategic wins

Elevance Health's Q2 performance reflects strong earnings growth and reaffirmed guidance, driven by solid segment performance and new business wins.
The company's strengths lie in its high Medicare rating, robust revenue growth in services, and strategic focus on value creation.
Challenges include sustaining growth momentum, managing funding cuts, and effectively integrating recent acquisitions for long-term success.
Opportunities exist in accelerating capabilities, expanding market share, optimizing operations, and leveraging workplace recognition for talent attraction and innovation.

Elevance Health faces Medicaid challenges, sees growth in AI investments

Elevance Health's Q3 earnings were impacted by elevated medical costs in Medicaid, leading to a reduction in full-year outlook. Despite challenges in the Medicaid business, the company's Medicare Advantage and Commercial businesses are performing well. Investments in AI and expansion of Carelon Services present growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Commercial and Specialty Business, Government Business, CarelonRx, and Other. The Commercial and Specialty Business segment provides insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance. The Government Business segment includes medicare and medicaid businesses, national government services, and services provided to the federal government. The CerelonRx segment offers formulary management, pharmacy networks, prescription drug database, member services, and mail order capabilities. The Other segment is involved in health services business focused on quality of healthcare by enabling and creating new care delivery and payment models. The company was founded in 1944 and is headquartered in Indianapolis, IN.

SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Elevance Health, Inc. (NYSE: ELV) or any of its executive officers violated securities laws by misrepresenting or failing to timely disclose material information to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Elevance Health, Inc. Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

Elevance Health, Inc. (NYSE:ELV ) UBS Global Healthcare Conference November 12, 2024 10:15 AM ET Company Participants Mark Kaye - Executive VP & CFO Conference Call Participants A.J. Rice - UBS A.J.

Elevance Health, Inc. (ELV) UBS Global Healthcare Conference (Transcript)

ELV encounters headwinds such as higher benefit costs, an increased debt level and member attrition in the Medicaid business, which raise concerns among investors.

Elevance Health Declines 20% in 3 Months: Time to Sell the Stock?

Cigna

Centene

Humana

Molina Healthcare

UnitedHealth Group

Several US health insurers saw notable stock price gains following the reelection of former US President Donald Trump amid an expectation of less federal scrutiny. Humana Inc. experienced the largest increase as its stock rose 10.7% from Nov. 1 through Nov. 6, increasing from $260.71 a share to $288.51 a share.

Trump Win Gives Some U.S. Health Insurers A Post-Election Bump On Wall Street

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Elevance Health, Inc. (NYSE: ELV) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Elevance Health, Inc. Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) announced today that senior management is scheduled to present at the UBS Global Healthcare Conference in Rancho Palos Verdes, California on November 12, at 7:15 a.m. Pacific Standard Time (PST) / 10:15 a.m. Eastern Standard Time (EST). All interested parties are invited to listen to a live webcast of the presentation by visiting www.elevancehealth.com and selecting the “Investors” link. You may also access the link here. For those unab.

Elevance Health Announces Appearance at UBS Global Healthcare Conference

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Ka.

Elevance Health Appoints Nathan Rich Vice President, Investor Relations

Accenture Plc

Amphenol

Domino's Pizza

Global Payments

Intuit

Lam Research

Mastercard

Microchip Technology

MSCI

Nordson

ResMed

Rollins

SPDR S&P 500 ETF Trust

Vanguard Dividend Appreciation ETF

Zoetis

The SPDR S&P 500 ETF Trust posted a loss of 0.89% in October, putting a pause on its strong run in 2024. The Top 15 dividend growth stocks for November 2024 offer an average dividend yield of 1.24% and appear to be about 23% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved an 11.33% compound annual growth rate.

My Top 15 High-Growth Dividend Stocks For November 2024

Align Technology

A. O. Smith

Enphase Energy

Erie Indemnity

First Solar

Genuine Parts

Mohawk Industries

Moderna

Qorvo

Super Micro Computer

Teradyne

Super Micro joined the list after a 33% drop on Wednesday.

These are the S&P 500's biggest laggards for October, down by as much as 29%

INDIANAPOLIS--(BUSINESS WIRE)-- #maternalhealth--The Elevance Health Foundation, the philanthropic arm of Elevance Health, today announces professional football player Ryan Kelly as its latest Elevance Health Champion. Designed to help increase awareness for critical health challenges and raise funds for local organizations that are making a healthy difference in their communities, the Elevance Health Champion program recognizes professional athletes and organizations who have dedicated their life to leading hea.

Elevance Health Foundation Names Professional Football Player Ryan Kelly as Next Elevance Health Champion

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has assigned a Long-Term Issue Credit Rating of “bbb+” (Good) to Elevance Health, Inc.'s (Elevance Health) (Indianapolis, IN) newly issued $350 million, 4.5% senior unsecured bonds, due 2026; $750 million, 4.750% senior unsecured bonds, due 2030; $750 million, 4.95% senior unsecured bonds, due 2031; $1.2 billion, 5.2% senior unsecured bonds, due 2035; $1.35 billion, 5.7% senior unsecured bonds, due 2055; and $800 million, 5.85% senior unsecured bonds, due.

AM Best Assigns Issue Credit Ratings to Elevance Health, Inc. New Senior Unsecured Bonds

Elevance Health (NYSE: ELV) recently reported its Q3 results, with revenues exceeding but earnings missing the consensus estimates. The company reported revenue of $44.7 billion and adjusted earnings of $8.37 per share, compared to the street estimates of $43.5 billion and $9.66, respectively.

What's Behind The 15% Fall For Elevance Health Stock?

Elevance Health's Q3 2024 results were disappointing with a significant increase in the benefit expense ratio and lowered earnings expectations for the full year. I take a close look at ELV's exposure to government plans and their profitability. I explain why I view Elevance stock as favorably valued even under very conservative near and long-term growth assumptions.

Elevance Health Stock: Looking Beyond Near-Term Issues, I'm A Buyer

Elevance Health Inc. ELV reported weaker-than-expected earnings for its third quarter on Thursday.

These Analysts Cut Their Forecasts On Elevance Health Following Q3 Earnings

Despite a disappointing Q3 report, Elevance Health remains attractive due to its relatively favorable valuation compared to UnitedHealth Group and a total shareholder yield of roughly 3.5%. Elevance's expansion into healthcare services through Carelon and continued strength in Medicare and Medicaid markets support long-term growth, especially given the industry's demographic tailwinds. Though 2024 is a “reset” year, Elevance management's outlook for 2025 and beyond points to strong potential margin recovery and continued earnings growth.

Elevance Health: Why Invest Over UnitedHealth Group?

Major U.S. equities indexes were mixed as earnings results from Taiwan Semiconductor Manufacturing (TSM) helped revitalize optimism around artificial intelligence (AI) and September retail sales data came in ahead of forecasts.

S&P 500 Gains and Losses Today: Health Insurers Slide as Elevance Cites Medicaid Declines

Elevance Health's Q3 earnings report led to a 14% stock price drop due to increased benefit expense ratio and declining EPS. The health insurance industry faces challenges, particularly in Medicare Advantage and Medicaid, affecting profitability and causing industry-wide share price declines. Elevance's management expects revenue growth in 2025 but acknowledges ongoing profitability issues, suggesting a cautious outlook for the near term.

Elevance Health: A Bad Q3 Was Almost Inevitable Given Industry Headwinds

ELV's third-quarter earnings are hurt by declining membership in Medicaid and Medicare, partially offset by improved product revenues.

Elevance Health's Q3 Earnings Miss Due to Medicaid Redeterminations

Elevance Health Inc.  ELV reported on Thursday third-quarter revenues of $44.7 billion, up 5.3% year-over-year, beating the consensus of $43.33 billion.

Why Is Elevance Health Stock Trading Lower On Thursday?

Elevance Health, Inc. (NYSE:ELV ) Q3 2024 Results Conference Call October 17, 2024 8:30 AM ET Company Participants Steve Tanal - Vice President of Investor Relations Gail Boudreaux - President and CEO Mark Kaye - CFO Pete Haytaian - President, Carelon Morgan Kendrick - President, Commercial Health Benefits Felicia Norwood - President, Government Health Benefits Conference Call Participants A.J. Rice - UBS Stephen Baxter - Wells Fargo Ben Hendrix - RBC Capital Markets Ann Hynes - Mizuho Erin Wright - Morgan Stanley Justin Lake - Wolfe Research Lisa Gill - JPMorgan Lance Wilkes - Bernstein Josh Raskin - Nephron Research Michael Hall - Baird Ryan Langston - Cowen Scott Fidel - Stephens Whit Mayo - Leerink Partners Sarah James - Cantor Fitzgerald Dave Windley - Jefferies Joanna Gajuk - Bank of America George Hill - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by, and welcome to the Elevance Health Third Quarter Earnings Conference Call.

Elevance Health, Inc. (ELV) Q3 2024 Earnings Call Transcript

Elevance Health stock is plunging Thursday after the insurer missed Q3 earnings expectations and lowered its full-year outlook. Here's what you need to know.

Elevance Health Stock Sinks as Medicaid Woes Hit Earnings

Doximity

HealthEquity

The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ELV, DOCS and HQY are set to gain the most.

3 Medical Services Stocks to Buy to Navigate Industry Challenges

The company's earnings missed expectations, the latest sign of how medical expenses are squeezing insurers' government businesses.

Elevance Shares Dive After Insurer Faces 'Unprecedented' Medicaid Challenge

Elevance Health (ELV) shares cratered Thursday after the insurer posted a lower-than-expected profit and slashed its outlook on falling Medicaid enrollments.

Elevance Health Stock Plunges on Profit Hit From Fall in Medicaid Memberships

Although the revenue and EPS for Elevance Health (ELV) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

News for Elevance Health Inc Stock (ELV)